rss
Br J Ophthalmol 2005;89:628-631 doi:10.1136/bjo.2004.050054
  • Clinical science
    • Extended reports

Penetration of moxifloxacin into the human aqueous humour after oral administration

  1. G Kampougeris1,
  2. A Antoniadou2,
  3. E Kavouklis1,
  4. Z Chryssouli2,
  5. H Giamarellou2
  1. 1Department of Ophthalmology, Laiko General Hospital, Athens, Greece
  2. 24th Department of Internal Medicine, Athens University School of Medicine, Attikon University General Hospital, Athens, Greece
  1. Correspondence to: Mr G Kampougeris Cardiff Eye Unit, University Hospital of Wales, Heath Park, Cardiff CF14 4XW, UK; gkampougerisyahoo.gr
  • Accepted 1 October 2004

Abstract

Aims: To determine the pharmacokinetics of moxifloxacin, a new generation fluoroquinolone, in the anterior chamber of the human uninflamed eye.

Methods: 35 patients undergoing cataract surgery received two doses of 400 mg of oral moxifloxacin with a 12 hour interval and were divided into six groups. Moxifloxacin levels in aqueous humour and serum were determined by a microbiological agar well diffusion technique at 2, 4, 6, 8, 10, and 12 hours after the second dose in each group respectively.

Results: Mean moxifloxacin levels in the anterior chamber were 1.20 (SD 0.35) μg/ml at the 2 hours group, 1.22 (0.48) μg/ml at the 4 hours group, 1.20 (0.45) μg/ml at the 6 hours group, 1.58 (0.38) μg/ml at the 8 hours group, 1.37 (0.44) μg/ml at the 10 hours group, and 1.23 (0.55) μg/ml at the 12 hours group. The mean ratio of aqueous to serum moxifloxacin level was 38%.

Conclusion: Moxifloxacin penetrates well into the anterior chamber of the human uninflamed eye after oral administration, reaching early significant levels, which are maintained for at least 12 hours and are much higher than the MIC90 values of Gram positive and Gram negative pathogens commonly implicated in intraocular infections with the exceptions of fluoroquinolone resistant staphylococci, MRSA, and Pseudomonas aeruginosa.

Footnotes

  • The authors have no proprietary interest in any of the antimicrobials mentioned in this manuscript.

This Article

  1. Abstract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.